Beyond Cancer Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Seite 2

Abstract #: 35688 represented an ex vivo analysis of T-cell response following administration of a 5-minute treatment of 50,000 or 100,000 ppm UNO in combination with 2-5 doses of 5 or 10 mg/kg Anti-CTLA-4. At day 5, mice treated with the combination therapy showed a statistically significant increase in the expression of proliferating T-helper cells versus mice treated with anti-mCTLA-4 alone. Mice treated with the combination therapy also demonstrated increases in cytotoxic T-cells, as well as a significant increase in active T-helper cells as represented by IFNƔ responses. At day 7, mice treated with either UNO alone or in combination with Anti-mCTLA-4 had significant increases in the expression of central memory T-cells. Further, at day 55, in cured mice treated with the combination therapy, the expression of the antigen specific T-cells was nearly statistically significant relative to untreated mice. A separate experiment carried out to day 100, demonstrated a statistically significant expression of antigen specific cytotoxic T-cells relative to naïve mice.

"This pooled analysis involving a significant number of mice across multiple experiments strengthens support for ongoing and future studies of UNO alone and in combination with immunotherapy for the treatment of solid tumors,” stated Dr. Frederick Dirbas, Chair of the Beyond Cancer Scientific Advisory Board.

Details of the company’s poster presentations are as follows:

Title:	Intratumoral Administration of Ultra High-Concentration Nitric Oxide (UNO) and Anti PD-1 Treatment Leads to High Tumor Regression Rates and Prolonged Survival in Tumor-Bearing Mice
Poster number:	A078
Session:	Poster Session A
Session Date and Time:	Thursday, October 12, 2023 / 12:30 pm – 4:00 pm EDT
Session Location:	Level 2, Exhibit Hall D
Abstract Number:	35782
Participant:	Yana Epshtein, PhD; Head of Translational Science, Beyond Cancer, Ltd.
Title:	Ultra-high concentration nitric oxide (UNO) enhances anti-CTLA-4 treatment activity and induces a durable anti-tumor response
Poster number:	C080
Session:	Poster Session C
Session Date and Time:	Saturday, October 14, 2023 / 12:30 pm – 4:00 pm EDT
Session Location:	Level 2, Exhibit Hall D
Abstract Number:	35688
Participant:	Yogev Sela, PhD; Head of In Vitro Studies, Beyond Cancer, Ltd.

About Nitric Oxide